The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
|Articles|June 10, 2021
FDA Approves Expansion of Community-Acquired Bacterial Pneumonia Therapy
Author(s)Contagion Editorial Team
Paratek’s omadacycline (Nuzyra) is granted approval for an oral-only dosing regimen in adults.
Advertisement
The Food and Drug Administration (FDA) approved an expansion for the therapy, Nuzyra, to include an oral-only dosing regimen for the treatment of Community-Acquired Bacterial Pneumonia (CABP) in adults.
Manufactured by biopharmaceutical company, Paratek, Nuzyra is a novel antibiotic with both once-daily oral and intravenous (IV) formulations. The oral-only dose for CABP has an initial dose of 300 mg twice on day 1 and 300 mg once daily thereafter for a total of 7 to 14 days. A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains.
“The approval of an oral-only dose regimen for Nuzyra in pneumonia represents a significant opportunity to offer clinicians the ability to treat patients in either the outpatient or primary care setting,” Adam Woodrow, president and chief commercial officer of Paratek, said. “Treating in this way potentially reduces or eliminates hospitalizations and the associated risk and costs from a hospital stay.”
Nuzyra had initially been approved by the FDA in October of 2018, and was indicated for the treatment of CABP and acute bacterial skin and skin structure infections (ABSSSI).
Advertisement
Related to this article
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
Recent urinary tract infection guideline updates from multiple international
medical societies highlight evolving recommendations, including a major shift
in classification, moving from anatomy- and risk factor–based definitions
toward distinguishing localized from systemic infections.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.